Current and historical daily PE Ratio for Novavax Inc (
) from 2020 to May 05 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Novavax stock (MEX:NVAX) PE ratio as of May 05 2024 is 0.
More Details
Novavax Inc (MEX:NVAX) PE Ratio (TTM) Chart
Novavax Inc (MEX:NVAX) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 990
- 1
- 2
- 3
- 4
- 5
- 6
- 11
| Novavax PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-05 | At Loss | 2024-02-27 | At Loss |
| 2024-05-03 | At Loss | 2024-02-26 | At Loss |
| 2024-05-02 | At Loss | 2024-02-23 | At Loss |
| 2024-04-30 | At Loss | 2024-02-22 | At Loss |
| 2024-04-29 | At Loss | 2024-02-21 | At Loss |
| 2024-04-26 | At Loss | 2024-02-20 | At Loss |
| 2024-04-25 | At Loss | 2024-02-19 | At Loss |
| 2024-04-24 | At Loss | 2024-02-16 | At Loss |
| 2024-04-23 | At Loss | 2024-02-15 | At Loss |
| 2024-04-22 | At Loss | 2024-02-14 | At Loss |
| 2024-04-19 | At Loss | 2024-02-13 | At Loss |
| 2024-04-18 | At Loss | 2024-02-12 | At Loss |
| 2024-04-17 | At Loss | 2024-02-09 | At Loss |
| 2024-04-16 | At Loss | 2024-02-08 | At Loss |
| 2024-04-15 | At Loss | 2024-02-07 | At Loss |
| 2024-04-12 | At Loss | 2024-02-06 | At Loss |
| 2024-04-11 | At Loss | 2024-02-05 | At Loss |
| 2024-04-10 | At Loss | 2024-02-02 | At Loss |
| 2024-04-09 | At Loss | 2024-02-01 | At Loss |
| 2024-04-08 | At Loss | 2024-01-31 | At Loss |
| 2024-04-05 | At Loss | 2024-01-30 | At Loss |
| 2024-04-04 | At Loss | 2024-01-29 | At Loss |
| 2024-04-03 | At Loss | 2024-01-26 | At Loss |
| 2024-04-02 | At Loss | 2024-01-25 | At Loss |
| 2024-04-01 | At Loss | 2024-01-24 | At Loss |
| 2024-03-27 | At Loss | 2024-01-23 | At Loss |
| 2024-03-26 | At Loss | 2024-01-22 | At Loss |
| 2024-03-25 | At Loss | 2024-01-19 | At Loss |
| 2024-03-22 | At Loss | 2024-01-18 | At Loss |
| 2024-03-21 | At Loss | 2024-01-17 | At Loss |
| 2024-03-20 | At Loss | 2024-01-16 | At Loss |
| 2024-03-19 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-29 | At Loss |
| 2024-02-29 | At Loss | 2023-12-28 | At Loss |
| 2024-02-28 | At Loss | 2023-12-27 | At Loss |
Novavax Inc (MEX:NVAX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Novavax Inc
NAICS : 325414
SIC : 2836
ISIN : US6700024010
Share Class Description:
MEX:NVAX: Ordinary SharesCompare
Compare
Traded in other countries / regions
NVAX.USANVV1.GermanyNVAX.Mexico IPO Date
2020-07-13Description
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers